1-3 of 3
Harald Fricke, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

Tobias Boch, MD, Thomas Luft, MD PhD, Maximilian Mossner, Johann-Christoph Jann, Daniel Nowak, MD, Christine Folz, Jennifer Klemmer, Susanne Brendel, Harald Fricke, MD, Claudia Kunz, PhD, Wolf-Karsten Hofmann, MD, Florian Nolte, MD
Journal: Blood
Blood (2016) 128 (22): 228.
https://doi.org/10.1182/blood.V128.22.228.228
Published: 2016
Journal Articles

The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)

Florian Nolte, MD, Claudia Kunz, Stephanie Fey, Julia Obländer, Susanne Brendel, Marion Klaumünzer, Maximilian Mossner, Johann-Christoph Jann, Stefanie Uhlig, Daniel Nowak, MD, Harald Fricke, MD, Wolf-Karsten Hofmann, MD
Journal: Blood
Blood (2013) 122 (21): 1562.
https://doi.org/10.1182/blood.V122.21.1562.1562
Published: 2013
Journal Articles

APG101 - a Novel Inhibitor of CD95/CD95L Signaling Prevents Graft-Versus-Host Disease without Disabling T Cell Effector Function and Anti-Tumor Activity,

Gudrun Strauss, PhD, Natalie Hartmann, PhD, Michael Kluge, PhD, Harald Fricke, MD, PhD, Klaus-Michael Debatin, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 4019.
https://doi.org/10.1182/blood.V118.21.4019.4019
Published: 2011